Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: A randomized double-blind placebocontrolled clinical trial

Fertility and Sterility

Volumn 93, Issue 7, 2010, Pages 2303-2310

  Romualdi, Daniela ^a   Giuliani, Maddalena ^a   Cristello, Francesca ^a   Fulghesu, Anna Maria ^c   Selvaggi, Luigi ^a   Lanzone, Antonio ^a,b   Guido, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Metformin; Normal weight; Normoinsulinemic; Ovaries; PCOS

Indexed keywords

HORMONE; HYDROXYPROGESTERONE; INSULIN; METFORMIN; PLACEBO; TESTOSTERONE; ANTIDIABETIC AGENT; SEX HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HIRSUTISM; HUMAN; MENSTRUAL CYCLE; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; OVARIAN ULTRASOUND; OVARY POLYCYSTIC DISEASE; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STEROIDOGENESIS; ULTRASOUND; BLOOD; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ECHOGRAPHY; METABOLISM; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY; STANDARD; TIME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; IDEAL BODY WEIGHT; INSULIN; METFORMIN; OVARY; PLACEBOS; POLYCYSTIC OVARY SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 77952557432     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.01.114     Document Type: Article

References (43)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18: 774-800.
3. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988;123:733-9.
4. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-9.
5. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-14.
6. Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, et al. Ultrasound in polycystic ovary syndrome\the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Hum Reprod 2007;22:2501-8.
7. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001;76:326-31.
8. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46.
9. Maciel GA, Soares Junior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60.
10. Palomba S, Falbo A, Orio F Jr, Manguso F, Russo T, Tolino A, et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in nonobese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005;20:2879-86.
11. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-6.
12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
13. Van Hooff MH, Voorhorst FJ, Koptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine feathures of polycystic ovary syndrome in a random population sample of 14-16 years old adolescents. Hum Reprod 1999;14:2223-9.
14. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57:320-6.
15. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999;48:167-72.
16. De Simone M, Verrotti A, Iughetti L, Palombo M, Farello G, Di Cesare E, et al. Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. J Endocrinol Invest 2001;24: 438-44.
17. Dietary Guidelines for Americans. Publication 261-495/20124. Washington, DC: U. S. Department of Agriculture, 1990.
18. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
19. Orsini LF, Venturoli S, Lorusso R, Pluchinotta V, Paradisi R, Bovicelli L. Ultrasonic findings in polycystic ovarian disease. Fertil Steril 1985;43: 709-14.
20. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2: 1375-9.
21. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157: 669-76.
22. Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: 3128-35.
23. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007;87:870-5.
24. Krstevska B, Ch Dimitrovski, Pemovska G, Misevska S, Dimova Z, Simeonova S, et al. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi 2006;27:57-66.
25. Hermann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-30.
26. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
27. Velazquez E, Acosta A, Mendoza SG Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-5.
28. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-in-duced resumption of normal menses in 39 of 43 (91%) previously amen-orrheic women with the polycystic ovary syndrome. Metabolism 1999;48:511-9.
29. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-54.
30. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without poly-cystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997;82:556-60.
31. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R. Pabuxccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsuli-nemic? Eur J Obstet Gynecol Reprod Biol 2005;123:204-11.
32. Kaleli S, Erel CT, Oral E, Elter K, Akman C, Colgar U. Ovarian stromal hypertrophy in polycystic ovary syndrome. J Reprod Med 1998;43: 893-7.
33. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf) 1994;41:557-62.
34. Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM, et al. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Hum Reprod 2006;21:3108-15.
35. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement ofinsulin resistance and ovarian morphology. Fertil Steril 2007;87:870-5.
36. Pache TD, de Jong FH, Hop WC, Fauser BC. Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signsofthe polycystic ovary syndrome. Fertil Steril 1993;59:544-9.
37. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 1989;30:459-70.
38. el Tabbakh GH, Lotfy I, Azab I, Rahman HA, Southren AL, Aleem FA. Correlationof the ultrasonic appearanceof the ovaries in polycystic ovarian disease and the clinical, hormonal, and laparoscopic findings. Am J Obstet Gynecol 1986;154:892-5.
39. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-67.
40. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-24.
41. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human steroidogenesis. Fertil Steril 2003;79:956-62.
42. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intraovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107-17.
43. Sonntag B, Götte M, Wülfing P, Schüring A, Kiesel L, Greb RR. Metfor-min alters insulin signalling and viability of human granulosa cells. Fertil Steril 2005;84:1173-9.